Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.1 USD | -1.37% | -9.25% | -3.83% |
16/05 | Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating | MT |
14/05 | US Equity Markets Close Higher Tuesday as Producer Prices Rise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.83% | 694.56Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-14.15% | 2.18TCr | |
-1.05% | 2.2TCr | |
-5.29% | 1.92TCr | |
-38.29% | 1.77TCr | |
-4.16% | 1.81TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Credit Suisse Raises Ascendis Pharma's Price Target to $89 From $82 After Q1 Skytrofa Revenue Beat Consensus, Keeps Neutral Rating